199 related articles for article (PubMed ID: 28900168)
1. Identification of key metabolic changes during liver fibrosis progression in rats using a urine and serum metabolomics approach.
Chang H; Meng HY; Liu SM; Wang Y; Yang XX; Lu F; Wang HY
Sci Rep; 2017 Sep; 7(1):11433. PubMed ID: 28900168
[TBL] [Abstract][Full Text] [Related]
2. Metabolic Profile Changes of CCl₄-Liver Fibrosis and Inhibitory Effects of Jiaqi Ganxian Granule.
Wang G; Li Z; Li H; Li L; Li J; Yu C
Molecules; 2016 May; 21(6):. PubMed ID: 27248993
[TBL] [Abstract][Full Text] [Related]
3. Dynamic changes of key metabolites during liver fibrosis in rats.
Yu J; He JQ; Chen DY; Pan QL; Yang JF; Cao HC; Li LJ
World J Gastroenterol; 2019 Feb; 25(8):941-954. PubMed ID: 30833800
[TBL] [Abstract][Full Text] [Related]
4. Chemical profile of Swertia mussotii Franch and its potential targets against liver fibrosis revealed by cross-platform metabolomics.
Zhang Y; Zhou Q; Ding X; Ma J; Tan G
J Ethnopharmacol; 2021 Jun; 274():114051. PubMed ID: 33746001
[TBL] [Abstract][Full Text] [Related]
5. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
[TBL] [Abstract][Full Text] [Related]
6. Toxic effects of chronic low-dose exposure of thioacetamide on rats based on NMR metabolic profiling.
Wei DD; Wang JS; Wang PR; Li MH; Yang MH; Kong LY
J Pharm Biomed Anal; 2014 Sep; 98():334-8. PubMed ID: 24996005
[TBL] [Abstract][Full Text] [Related]
7. Metabolomics combined with pattern recognition and bioinformatics analysis methods for the development of pharmacodynamic biomarkers on liver fibrosis.
Fang J; Wang L; Wang Y; Qiu M; Zhang Y
Mol Biosyst; 2017 Jul; 13(8):1575-1583. PubMed ID: 28671700
[TBL] [Abstract][Full Text] [Related]
8. [Inhibitory effect of Scutellariae Radix on hepatic fibrosis based on urinary metabonomic].
Chang H; Meng HY; Wang Y; Teng Z; Liu SM
Zhongguo Zhong Yao Za Zhi; 2018 May; 43(10):2140-2146. PubMed ID: 29933684
[TBL] [Abstract][Full Text] [Related]
9. Serum metabolic profiling of rats infected with
Han S; Zhang X; Ding J; Li X; Zhang X; Jiang X; Duan S; Sun B; Hu X; Gao Y
Front Cell Infect Microbiol; 2022; 12():1040330. PubMed ID: 36683702
[TBL] [Abstract][Full Text] [Related]
10. Identification of key metabolites during cisplatin-induced acute kidney injury using an HPLC-TOF/MS-based non-targeted urine and kidney metabolomics approach in rats.
Qu X; Gao H; Sun J; Tao L; Zhang Y; Zhai J; Song Y; Hu T; Li Z
Toxicology; 2020 Feb; 431():152366. PubMed ID: 31926187
[TBL] [Abstract][Full Text] [Related]
11. Urinary and Plasma Metabolomics Identify the Distinct Metabolic Profile of Disease State in Chronic Mouse Model of Multiple Sclerosis.
Singh J; Cerghet M; Poisson LM; Datta I; Labuzek K; Suhail H; Rattan R; Giri S
J Neuroimmune Pharmacol; 2019 Jun; 14(2):241-250. PubMed ID: 30315511
[TBL] [Abstract][Full Text] [Related]
12. Serum Metabolomic Characterization of Liver Fibrosis in Rats and Anti-Fibrotic Effects of Yin-Chen-Hao-Tang.
Zhang H; Wang X; Hu P; Zhou W; Zhang M; Liu J; Wang Y; Liu P; Luo G
Molecules; 2016 Jan; 21(1):E126. PubMed ID: 26805802
[TBL] [Abstract][Full Text] [Related]
13. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
[TBL] [Abstract][Full Text] [Related]
14. Study of the metabolomics characteristics of patients with metabolic syndrome based on liquid chromatography quadrupole time-of-flight mass spectrometry.
Wu N; Wang W; Yi M; Cheng S; Wang D
Ann Endocrinol (Paris); 2018 Feb; 79(1):37-44. PubMed ID: 29246383
[TBL] [Abstract][Full Text] [Related]
15. Integrated plasma and urine metabolomics coupled with HPLC/QTOF-MS and chemometric analysis on potential biomarkers in liver injury and hepatoprotective effects of Er-Zhi-Wan.
Yao W; Gu H; Zhu J; Barding G; Cheng H; Bao B; Zhang L; Ding A; Li W
Anal Bioanal Chem; 2014 Nov; 406(28):7367-78. PubMed ID: 25245419
[TBL] [Abstract][Full Text] [Related]
16. Effects of Shu Gan Jian Pi formula on rats with carbon tetrachloride‑induced liver fibrosis using serum metabonomics based on gas chromatography‑time of flight mass spectrometry.
Jiang H; Qin XJ; Li WP; Ma R; Wang T; Li ZQ
Mol Med Rep; 2017 Oct; 16(4):3901-3909. PubMed ID: 29067456
[TBL] [Abstract][Full Text] [Related]
17. Integrated metabolomic profiling for analysis of antilipidemic effects of
Yang XX; Wei JD; Mu JK; Liu X; Dong JC; Zeng LX; Gu W; Li JP; Yu J
World J Gastroenterol; 2018 Dec; 24(48):5505-5524. PubMed ID: 30622379
[TBL] [Abstract][Full Text] [Related]
18. Molecular classification of liver cirrhosis in a rat model by proteomics and bioinformatics.
Xu XQ; Leow CK; Lu X; Zhang X; Liu JS; Wong WH; Asperger A; Deininger S; Eastwood Leung HC
Proteomics; 2004 Oct; 4(10):3235-45. PubMed ID: 15378689
[TBL] [Abstract][Full Text] [Related]
19. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R
Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807
[TBL] [Abstract][Full Text] [Related]
20. Altered Metabolic Profile and Adipocyte Insulin Resistance Mark Severe Liver Fibrosis in Patients with Chronic Liver Disease.
Gaggini M; Carli F; Rosso C; Younes R; D'Aurizio R; Bugianesi E; Gastaldelli A
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31888144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
